Company profile
Artificial Intelligence and Machine Learning enabled Information Systems and Solutions | AES Group
We strive to be true partners with our customers by helping them successfully achieve their objectives, on projects both large and small, through innovation and creative solutions.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
TM01 | Transaction MzQ0MjY5NDM1MGFkaXF6a2N4
Published 11 Nov 2024 05:52
AP01 | Transaction MzQ0MjY5MzY5MGFkaXF6a2N4
Published 11 Nov 2024 05:40
AP01 | Transaction MzQ0MjY5MzUxNGFkaXF6a2N4
Published 11 Nov 2024 05:36
CS01 | Transaction MzQzMTUxMTU1MGFkaXF6a2N4
Published 07 Aug 2024 14:28
Company registered at Companies House
1 Oct 2022 to 31 Mar 2025
Faecal immunochemical testing (FIT) measures faecal haemoglobin concentration (f-Hb). FIT can be used to manage patients presenting in primary care with unexplained lower gastrointestinal (GI) symptoms that may be indicative of bowel cancer in primary care prior to (or alongside) an urgent referral, or for triaging in secondary care to guide the managemen...
1 Nov 2021 to 31 Jan 2024
**NEED:** The UK's Bowel Cancer Screening Programme (BCSP) has been revolutionised by improved diagnostic methodology, the Faecal Immunochemical Test (FIT). FIT is easy to undertake (only one sample required), and so screening participation has increased from 59.4% to 67.5% of eligible adults aged \>50 years. Any participant exceeding a pre-determined FIT...
1 Nov 2018 to 31 Oct 2019
"Bowel cancer screening services invite asymptomatic persons aged \>60 years to conduct guaiac-based Faecal Occult Blood testing (gFOBt) every two years. From Autumn 2018, NHS England's Bowel Cancer Screening Programme (BCSP; commissioned by Public Health England; PHE) will roll-out Faecal Immunochemical Test (FIT) to replace gFOBt. FIT is simpler, more s...
